Pavmed Stock Price, News & Analysis

Lucid Diagnostics Inc. (Nasdaq: LUCD) has been named a finalist for the MD+DI Medtech Company of the Year 2022 award, recognizing its efforts in cancer prevention through innovative diagnostics. The company's EsoGuard^®, a molecular diagnostic tool for early detection of esophageal cancer, represents a critical advancement in screening at-risk GERD patients. The winner will be announced the week of December 12, 2022. With esophageal cancer mortality rates high, Lucid's development of non-invasive screening tools has significant potential to reduce preventable deaths.

Lucid Diagnostics Inc. (Nasdaq: LUCD) announced promising results from a presentation at the AACR Special Conference showcasing the EsoCheck esophageal cell sampling procedure. Conducted on 687 patients, it achieved a 98% success rate, even with severe gag reflex cases. The average procedure took 3.5 minutes, and over 90% of samples yielded sufficient DNA for testing. EsoCheck and its companion EsoGuard test are pivotal for early detection of esophageal precancer, with recommendations from major guidelines, addressing the high mortality associated with esophageal cancer.

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) announced significant updates in its business and financial performance for Q3 2022. The EsoGuard tests showed a steady 28% sequential growth and a remarkable 436% annual increase, with 1,088 tests conducted. Lucid Diagnostics is expanding its network, targeting 16 centers by year-end. Operating expenses reached approximately $23.4 million, with a GAAP net loss of $26.2 million. Cash reserves were reported at $56.8 million. Veris Health is set for a commercial launch of its Cancer Care Platform by year-end, enhancing growth prospects.

Lucid Diagnostics reported a significant increase in its EsoGuard test volume, achieving a 28% growth sequentially and a remarkable 436% year-over-year increase. The company's financial results for Q3 2022 reflected revenues of $0.1 million against operating expenses of approximately $14.4 million, leading to a GAAP net loss of $14.3 million, or $(0.39) per share. Lucid is focused on cash preservation while expanding its sales team and test centers, with an aim to continue growth in a challenging reimbursement environment. The company had $26.9 million in cash at the end of September 2022.

PAVmed Inc. (NASDAQ: PAVM, PAVMZ), a diversified medical technology company, announced its participation in the Technologies Ushering in Next-Generation Diagnostics, Therapies, and Surgeries panel at the BTIG Digital Health Forum on November 21, 2022. CEO Lishan Aklog will discuss PAVmed's digital health subsidiary, Veris Health, and its innovative solutions in cancer care. PAVmed will also hold 1x1 virtual meetings during the event. For additional details, visit PAVmed.com.

Lucid Diagnostics Inc. (Nasdaq: LUCD), a cancer prevention medical diagnostics company, announced that its CEO, Lishan Aklog, M.D., will present at the CG MedTech, Diagnostics and Digital Health & Services Forum on November 17, 2022, from 11:00 am to 11:25 am EST at The Westin New York Grand Central. The presentation will focus on Lucid’s breakthrough EsoGuard Esophageal DNA Test, which is used for early detection of esophageal precancer in patients with gastroesophageal disease (GERD). A webcast of the presentation will be available for replay on Lucid's investor relations website.

Lucid Diagnostics (Nasdaq: LUCD) has begun high-volume production of its EsoCheck® Esophageal Cell Collection Devices at Coastline International, significantly reducing production costs by approximately 60%. This transition enhances manufacturing capacity to 20,000 units annually, with potential scalability to over one million units. The EsoCheck device is vital for the EsoGuard® Esophageal DNA Test, aimed at early detection of esophageal precancer in GERD patients. This strategic move underscores Lucid's commitment to improving cancer screening and prevention.

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) will host a business update conference call on November 15, 2022, at 4:30 PM EDT. CEO Lishan Aklog and CFO Dennis McGrath will share insights on the company’s growth strategy and third-quarter 2022 financial results. The call can be accessed via telephone or live webcast on their investor relations website. PAVmed is a commercial-stage medical technology company, operational in diagnostics and digital health, with subsidiaries like Lucid Diagnostics focusing on cancer prevention.

Lucid Diagnostics Inc. (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics company, will host a conference call on November 14, 2022, at 4:30 PM EDT. CEO Lishan Aklog and CFO Dennis McGrath will discuss a business update and third-quarter financial results. Investors can join the call via telephone or webcast. Lucid focuses on early cancer detection in GERD patients with its EsoGuard Esophageal DNA Test and EsoCheck device, both crucial for preventing esophageal cancer.